Status:
COMPLETED
Efficacy and Safety of Lumiracoxib
Lead Sponsor:
Novartis
Conditions:
Osteoarthritis
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
This trial assessed the safety and efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to a single dose of celecoxib 200mg. It also assessed safety and efficacy of 400mg lumiracoxi...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Osteoarthritis of the knee
- Pain intensity at baseline of at least 50mm on a 100mm visual analog scale
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT00267215
Start Date
November 1 2000
Last Update
May 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Nuremberg, Germany